Zim Laboratories Share Price Target 2026 Analyst Forecast Bull and Bear Case
- June 26, 2026
- Posted by: Kunal Singla
- Category: News
The Zim Laboratories share price target 2026 is Rs 150, implying approximately 20 percent upside from the current market price of Rs 124.9 (NSE: ZIMLAB). With Q4 FY26 results released in 2026 and Specialty Pharma Oral Drug Delivery tailwinds in focus, the Rs 150 price objective is supported by the FY27 earnings recovery thesis.
Zim Laboratories (NSE: ZIMLAB) is a Specialty Pharma Oral Drug Delivery company trading at Rs 124.9 with a market capitalisation of Rs 663 crore. Analysts have set the Zim Laboratories share price target at Rs 150 for 2026, based on FY27 earnings projections and sector re-rating potential. According to Ankit Jaiswal, Senior Research Analyst at Univest, the Rs 150 price objective reflects improving fundamentals in the Specialty Pharma Oral Drug Delivery space. This article covers the complete 2026 price forecast including sector tailwinds, key risks, and bull and bear scenarios.
Click Here – Get Free Investment Predictions
Zim Laboratories Share Price Target 2026: Key Takeaways
- Zim Laboratories share price target 2026: Rs 150 (20% upside from CMP Rs 124.9)
- Bull case: Rs 180 | Bear case: Rs 99.9
- Ticker: ZIMLAB | Sector: Specialty Pharma Oral Drug Delivery | MCap: Rs 663 crore
- 52W range: Rs 59.31 to Rs 133.9 | PE: 18x
- Key catalyst: Q4 FY26 results and FY27 earnings confirmation in 2026
- Key risk: FY27 earnings miss or FII outflows from Indian equities
Zim Laboratories Company Overview
Zim Laboratories (NSE: ZIMLAB) is a Nagpur-based specialty pharmaceutical company developing and manufacturing orally dissolving strips, novel drug delivery systems, and nutraceuticals for domestic branded generic and export markets. At CMP Rs 124.9 against a 52 week range of Rs 59.31 to Rs 133.9, the stock trades at a meaningful discount to its 52 week high. Market capitalisation is Rs 663 crore with trailing PE of 18x. Compared to peers in specialty pharma like Indoco Remedies and Bliss GVS Pharma, Zim Laboratories is positioned as a potential re-rating candidate toward the Rs 150 price objective on FY27 earnings delivery.
| Parameter | Value |
|---|---|
| NSE Ticker | ZIMLAB |
| Sector | Specialty Pharma Oral Drug Delivery |
| CMP (2026) | Rs 124.9 |
| 52 Week High | Rs 133.9 |
| 52 Week Low | Rs 59.31 |
| Market Cap | Rs 663 crore |
| Trailing PE | 18x |
| 12-Month Analyst Target | Rs 150 |
| Bull Case Target | Rs 180 |
| Bear Case Target | Rs 99.9 |
Why Is the Zim Laboratories Share Price Target Set at Rs 150 for 2026
FY27 Earnings Recovery and Revenue Acceleration
The Zim Laboratories share price target of Rs 150 rests on analyst projections of 15 to 20 percent PAT growth in FY27. Ankit Jaiswal at Univest notes that Q4 FY26 results confirming the earnings trajectory are the most direct catalyst for re-rating from CMP Rs 124.9.
Structural Sector Tailwinds in Specialty Pharma Oral Drug Delivery
The Specialty Pharma Oral Drug Delivery sector is expanding on the back of India’s domestic demand growth, PLI scheme support, and rising corporate investment. Zim Laboratories’s position among peers in specialty pharma like Indoco Remedies and Bliss GVS Pharma creates a structural growth runway, with sustained outperformance being one of the key conditions for the Rs 180 bull case to materialise.
RBI Rate Cut Cycle and Lower Cost of Capital
India’s RBI rate cut cycle in 2026 is reducing borrowing costs and stimulating end market demand. Lower interest costs improve Zim Laboratories’s EPS trajectory, narrowing the gap between current earnings and the FY27 estimates that underpin the Rs 150 analyst consensus.
Union Budget 2026-27 Capex Push and Policy Support
Budget 2026-27’s Rs 11.21 lakh crore infrastructure capex and PLI scheme continuity create a favourable backdrop for Zim Laboratories’s Specialty Pharma Oral Drug Delivery operations, improving the probability of achieving the Rs 150 price objective through FY27 earnings delivery.
FII Flow Normalisation After the 2026 Tariff Shock
As global macro conditions normalise through 2026, FII flows into quality Indian equities are gradually recovering. At 18x PE, Zim Laboratories is positioned as a beneficiary of institutional reallocation toward the Rs 180 bull case over the medium term.
Zim Laboratories Share Price Targets: Short Term, 12 Month, and Long Term
Short Term Zim Laboratories Share Price Target
Near-term support for Zim Laboratories is anchored close to the 52 week low of Rs 59.31. A confirmed Q4 FY26 earnings recovery in 2026 is the trigger for an initial 10 to 15 percent re-rating from CMP Rs 124.9.
12-Month Zim Laboratories Share Price Target 2026
The 12-month Zim Laboratories share price target 2026 is Rs 150, implying approximately 20 percent upside from CMP Rs 124.9. This base case assumes in-line FY27 earnings delivery and partial normalisation of FII flows.
Long Term Zim Laboratories Share Price Target: FY27 to FY28
The long term Zim Laboratories share price target for FY27 to FY28 is Rs 180 in the bull case, requiring full earnings delivery, re-rating among peers in specialty pharma like Indoco Remedies and Bliss GVS Pharma, and sustained institutional buying over a 2 to 3 year horizon.
Bull Case and Bear Case Scenarios for Zim Laboratories in 2026
Bull Case Zim Laboratories Share Price Target: Rs 180
The bull case Zim Laboratories share price target of Rs 180 materialises when FY27 earnings beat analyst estimates, Specialty Pharma Oral Drug Delivery tailwinds accelerate, and FII flows return strongly to Indian equities, representing approximately 45 percent potential upside from CMP Rs 124.9.
Bear Case Zim Laboratories Share Price Target: Rs 99.9
The bear case Zim Laboratories share price target of Rs 99.9 materialises if FY27 earnings disappoint or FII outflows depress the broader market, risking a test of support near the 52 week low of Rs 59.31.
| Scenario | Target | Key Conditions |
|---|---|---|
| Bull Case | Rs 180 | FY27 beat, sector re-rating, FII inflows |
| Base Case (Analyst Target) | Rs 150 | In-line FY27 delivery, partial FII recovery |
| Bear Case | Rs 99.9 | FY27 miss, guidance cut, FII outflows persist |
Key Risks That Could Derail the Zim Laboratories 2026 Price Objective
Global Macro and US Tariff Headwinds
Prolonged tariff tensions and global demand slowdown remain prominent macro risks to the Zim Laboratories share price target of Rs 150, with FII outflows being the direct transmission mechanism to Indian equity valuations.
FY27 Earnings Miss and Guidance Risk
An FY27 earnings miss or downward guidance revision would compress valuation multiples and is the most direct company-specific risk to the Rs 150 analyst price objective. Investors must monitor quarterly results and management commentary closely.
Competitive Intensity Among Specialty Pharma Oral Drug Delivery Peers
Intensifying competition from peers in specialty pharma like Indoco Remedies and Bliss GVS Pharma could compress Zim Laboratories’s market share and pricing power, a structural risk that must be weighed when assessing the defensibility of the earnings trajectory underpinning the Rs 150 analyst target for 2026.
Liquidity Risk and FII Selling Pressure
Sustained FII outflows from Indian equities can delay the re-rating process regardless of company-level improvement. Investors should maintain position sizing discipline and stop losses to protect capital.
How to Invest in Zim Laboratories
Check the Univest Screener for live data
Before considering any investment based on the Zim Laboratories share price target of Rs 150, review Q4 FY26 results and FY27 guidance released in 2026. Focus on revenue growth, margin trends, and management commentary on Specialty Pharma Oral Drug Delivery sector demand.
Open a Demat account with a SEBI registered stockbroker to trade Zim Laboratories (NSE: ZIMLAB) with full regulatory protection. Study the competitive landscape among peers in specialty pharma like Indoco Remedies and Bliss GVS Pharma before executing any position.
Plan your entry using the 52 week low of Rs 59.31 as a key support reference. A confirmed FY27 earnings uptick validates the entry case for the Rs 150 price objective. Always set a stop loss below the 52 week low.
Restrict any single stock to 3 to 5 percent of your total equity portfolio. Always consult a SEBI registered financial advisor before investing. SEBI Registration No. INH000013776.
Download the Univest iOS App or the Univest Android App to track Zim Laboratories’s live share price and receive daily stock recommendations.
Disclaimer Note: The securities quoted, if any, are for illustration only and are not recommendatory. This content is for educational purposes only and does not constitute investment advice. Investments in securities are subject to market risk. Read all related documents carefully before investing. SEBI Registration No. INH000013776.
FAQs on Zim Laboratories Share Price Target 2026
What is the Zim Laboratories share price target for 2026?
Ans. The Zim Laboratories share price target 2026 is Rs 150, implying approximately 20 percent upside from CMP Rs 124.9. Bull case is Rs 180, bear case is Rs 99.9.
What was the Zim Laboratories share price target for 2025?
Ans. The 2025 price objective for Zim Laboratories was based on FY26 earnings projections. The current 2026 analyst consensus is Rs 150, reflecting FY27 growth potential from CMP Rs 124.9.
Is Zim Laboratories a good investment at Rs 124.9?
Ans. At Rs 124.9, Zim Laboratories offers potential upside toward Rs 150 if FY27 earnings recover. Whether this represents a good entry depends on individual risk tolerance. Consult a SEBI registered financial advisor before investing.
What are the key risks to the Zim Laboratories share price target 2026?
Ans. Key risks to the Zim Laboratories share price target of Rs 150 include FY27 earnings miss, global tariff headwinds, FII outflows, and competitive pressure in Specialty Pharma Oral Drug Delivery. Monitoring quarterly results is essential.
What is the 52 week high and low of Zim Laboratories?
Ans. The 52 week high of Zim Laboratories is Rs 133.9 and the 52 week low is Rs 59.31. At CMP Rs 124.9, the stock offers potential upside toward the Rs 150 price objective.
What are the main growth catalysts for Zim Laboratories in 2026?
Ans. Key catalysts include FY27 PAT recovery, Specialty Pharma Oral Drug Delivery tailwinds, RBI rate cuts in 2026, Budget 2026-27 policy support, and normalisation of FII flows into Indian equities.
How does Zim Laboratories compare to its peers?
Ans. Zim Laboratories operates in Specialty Pharma Oral Drug Delivery alongside peers in specialty pharma like Indoco Remedies and Bliss GVS Pharma. At CMP Rs 124.9 with MCap Rs 663 crore, it is a potential re-rating candidate toward the Zim Laboratories share price target of Rs 150 on FY27 delivery.
What is the Zim Laboratories share price target for 2027?
Ans. The long-term Zim Laboratories share price target for FY27 to FY28 is Rs 180 in the bull case, assuming earnings growth, sector re-rating, and FII inflows. Consult a SEBI registered financial advisor for personalised guidance.
